Riverhead Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Riverhead Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$14K	Hold	375	–	–	﹤0.01%	1479
2019 Q2	$17K	Sell	375 -17	-4%	-$798	﹤0.01%	1498
2019 Q1	$16K	Buy	392 +26	+7%	+$1.17K	﹤0.01%	1477
2018 Q4	$17K	Sell	366 -100	-21%	-$4.82K	﹤0.01%	1471
2018 Q3	$21K	Buy	+466	New	+$21.4K	﹤0.01%	1532
2018 Q2	–	Sell	-103	Closed	-$7K	–	1553
2018 Q1	$7K	Buy	+103	New	+$7.56K	﹤0.01%	1527
2015 Q2	–	Sell	-25,455	Closed	-$2.36M	–	622
2015 Q1	$2.36M	Buy	+25,455	New	+$1.64M	0.04%	457

Other funds holding ESPR

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Riverhead Capital Management's ESPR Position: Q3 2019 in Review

Riverhead Capital Management held its Esperion Therapeutics (ESPR) position steady in Q3 2019 at 375 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #1479.

Riverhead Capital Management first reported a position in ESPR in Q1 2015 and has held it in 7 quarters since. The position peaked at $2.36M in Q1 2015. 152 funds tracked by Wall St. Rank hold ESPR as of Q3 2019.

Riverhead Capital Management held 375 shares of Esperion Therapeutics worth $14K as of Q3 2019.
Riverhead Capital Management left its Esperion Therapeutics share count unchanged in Q3 2019.
Esperion Therapeutics made up ﹤0.01% of Riverhead Capital Management's portfolio in Q3 2019, its #1479 holding.
Riverhead Capital Management first reported a position in Esperion Therapeutics in Q1 2015 and has held it in 7 quarters since.
Riverhead Capital Management's Esperion Therapeutics position peaked at $2.36M in Q1 2015.
152 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.